TScan Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Tscan Therapeutics

19/08/2021 19:53

* TScan Therapeutics Inc  TCRX.OQ  reported a quarterly adjusted
loss of $7.69​​ per share for the quarter ended in June. The
mean expectation of three analysts for the quarter was for a
loss of $2.87 per share.
* Revenue was $2.85 million​;  analysts expected $1.07 million. 
* TScan Therapeutics Inc's reported EPS for the quarter was a
loss of $7.69​.
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* The company reported a quarterly loss of $10.67 million.
* Wall Street's median 12-month price target for TScan
Therapeutics Inc is $22.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated August 19 at 06:52 p.m.  ​All
figures in US dollars unless otherwise stated